Vitamins and Cancer: A Systematic Evidence Review Anchored on Vitamin B6 (PLP) Suppressing Pancreatic Cancer
Deep Research Report — Report date: 2026-08-14
Background
A 2026 in vitro study by Feehan et al. in *Molecular Nutrition & Food Research* (DOI: 10.1002/mnfr.70333, PMID: 41560327, RMIT University) found that pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, suppressed human pancreatic adenocarcinoma BxPC3 cells. Widely shared headlines claimed "nearly 50% of cancer cells killed." This report systematically evaluates the strength of anticancer evidence for common vitamins (B6, C, D, E, folate, A/retinoids), graded on a Level I–VII evidence pyramid.
Key points on the anchor study (B6/PLP, Level III in vitro)
- Dose-dependent growth inhibition of BxPC3 (KRAS-mutant) cells at 125–500 µg/mL; apoptosis rose from 2.38% to 45.4%.
- Mitochondrial membrane depolarization, elevated superoxide generation, and downregulation of KRAS, E2F, G2M checkpoint, and mTOR-related transcripts.
- Inhibition of mitochondrial aspartate/glutamate carriers (AGC1/2), cutting off glutamine-dependent metabolism.
- In PANC-1 cells, PLP altered transcripts (TNF signaling, unfolded protein response) rather than blocking proliferation — a simplification in popular coverage, not a contradiction.
- Supporting evidence: PLP deficiency cooperates with oncogenic Ras to induce tumors in *Drosophila* (Pilesi et al., 2024, *Cell Death and Disease*); meta-analyses (~1.96 million participants) link higher B6 intake and blood PLP with lower multi-site cancer risk. No RCTs exist.
- Vitamin A / ATRA (Level I, translated): All-trans retinoic acid induces ~90% complete remission in acute promyelocytic leukemia via differentiation therapy targeting PML-RARα; combined with anthracyclines and arsenic trioxide, cure rates reach ~70–95%. The only vitamin-derived standard anticancer drug — and *not* extrapolable to dietary vitamin A, which is toxic in excess.
- Vitamin C (mechanism Level III, clinical Level I–II early): Oral intake is capped at ~250 µmol/L; IV infusion reaches 25–30 mmol/L, where vitamin C acts as a pro-oxidant generating H₂O₂. Mechanisms include ROS/ATP depletion, TET-mediated demethylation, HIF-1α degradation, and immune modulation. A 2025 meta-analysis (PROSPERO: CRD42024600634) suggests longer overall survival with IV vitamin C, with moderate certainty; a phase III trial in metastatic colorectal cancer showed no PFS benefit overall, but a possible RAS-mutant subgroup benefit. Not FDA-approved.
- Vitamin D (Level I): Meta-analyses of RCTs (30 trials, 18,808 participants; 10 trials, 81,362 participants) show no significant reduction in cancer incidence; mortality reductions (~12%) are low-quality signals.
- Vitamin E (Level I): The SELECT trial (35,000+ men) showed high-dose vitamin E (400 IU/day) increased prostate cancer risk by 17% (HR 1.17, P=0.008) — net harm, contrasting with earlier ATBC results in smokers.
- Folate (Level I, heterogeneous): Deficiency raises colorectal cancer risk, but supplementation after existing lesions may promote adenomas; benefit depends on baseline folate status (RR 0.61 in low-baseline vs. RR 1.28 in high-baseline individuals).
- Feehan, J., et al. (2026). Pyridoxal 5′-phosphate suppresses growth of pancreatic adenocarcinoma cells in vitro via regulation of oncogenic RAS. *Molecular Nutrition & Food Research, 70*, e70333. https://doi.org/10.1002/mnfr.70333
- Pilesi, E., et al. (2024). Vitamin B6 deficiency cooperates with oncogenic Ras to induce malignant tumors in Drosophila. *Cell Death and Disease, 15*, 388. https://doi.org/10.1038/s41419-024-06787-3
- Qu, J., et al. (2025). Overall and progression-free survival of patients with malignant neoplasm following intravenous vitamin C. *International Journal for Vitamin and Nutrition Research, 95*(3). https://doi.org/10.31083/IJVNR37372
- Keum, N., & Giovannucci, E. (2018). Cancer and vitamin D supplementation: A systematic review and meta-analysis. PMID: 29635490
- Zhang, X., & Niu, W. (2019). Meta-analysis of RCTs on vitamin D supplement and cancer incidence and mortality. *Bioscience Reports*. https://doi.org/10.1042/BSR20190369
- Klein, E. A., et al. (2011). Vitamin E and the risk of prostate cancer: The SELECT trial. *JAMA, 306*(14), 1549–1556.
- Cole, B. F., et al. (2007). Folic acid for the prevention of colorectal adenomas. *JAMA, 297*(21), 2351–2359.
- Wu, K., et al. (2009). A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. *American Journal of Clinical Nutrition, 90*(6), 1623–1631.
- Differentiation therapy with ATRA in APL: PMID 9126315; PMID 27265273.
Comparative evidence for other vitamins
The translational chasm
The in vitro effective PLP concentrations (125–500 µg/mL ≈ mmol/L) are 2–3 orders of magnitude higher than serum PLP achievable by oral supplementation (µmol/L). Equating in vitro apoptosis rates with human efficacy is a classic in vitro–in vivo fallacy. The study's value is mechanistic, not a basis for taking B6 supplements against cancer.
Conclusions
1. Vitamin anticancer claims span from proven drugs (ATRA for APL) to unproven in vitro phenomena (B6/PLP, oral vitamin C). 2. Vitamin D does not reduce cancer incidence; high-dose vitamin E is harmful; folate is stage- and baseline-dependent. 3. Vitamins are biphasic: deficiency causes genomic instability, excess causes harm (B6 tolerable upper limit ~100 mg/day vs. recommended ~1.2–1.5 mg/day). 4. Public advice: obtain vitamins from a balanced diet; do not take high-dose supplements for "anticancer" purposes. This report is not medical advice.